- Home
- PMAX vs GRI Comparison
PMAX vs GRI Comparison
Compare PMAX & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMAX
- GRI
- Stock Information
- Founded
- PMAX 2019
- GRI 2018
- Country
- PMAX Hong Kong
- GRI United States
- Employees
- PMAX N/A
- GRI N/A
- Industry
- PMAX
- GRI Biotechnology: Pharmaceutical Preparations
- Sector
- PMAX
- GRI Health Care
- Exchange
- PMAX Nasdaq
- GRI Nasdaq
- Market Cap
- PMAX 5.3M
- GRI 4.3M
- IPO Year
- PMAX 2024
- GRI N/A
- Fundamental
- Price
- PMAX $1.98
- GRI $1.81
- Analyst Decision
- PMAX
- GRI Strong Buy
- Analyst Count
- PMAX 0
- GRI 2
- Target Price
- PMAX N/A
- GRI $22.50
- AVG Volume (30 Days)
- PMAX 40.7K
- GRI 132.2K
- Earning Date
- PMAX 09-23-2025
- GRI 11-14-2025
- Dividend Yield
- PMAX N/A
- GRI N/A
- EPS Growth
- PMAX N/A
- GRI N/A
- EPS
- PMAX N/A
- GRI N/A
- Revenue
- PMAX $4,799,100.00
- GRI N/A
- Revenue This Year
- PMAX N/A
- GRI N/A
- Revenue Next Year
- PMAX N/A
- GRI N/A
- P/E Ratio
- PMAX N/A
- GRI N/A
- Revenue Growth
- PMAX N/A
- GRI N/A
- 52 Week Low
- PMAX $1.83
- GRI $1.10
- 52 Week High
- PMAX $27.44
- GRI $16.92
- Technical
- Relative Strength Index (RSI)
- PMAX 41.87
- GRI 49.73
- Support Level
- PMAX $2.42
- GRI $1.58
- Resistance Level
- PMAX $2.36
- GRI $1.89
- Average True Range (ATR)
- PMAX 0.17
- GRI 0.15
- MACD
- PMAX -0.11
- GRI -0.00
- Stochastic Oscillator
- PMAX 7.61
- GRI 69.70
About PMAX Powell Max Limited
Powell Max Ltd is an financial communications services provider. Its financial communications services cover a full range of financial printing, corporate reporting, communications and language support services from inception to completion, including typesetting, proofreading, translation, design, printing, electronic reporting, newspaper placement and distribution. It operates in a single business segment which is the provision of corporate financial communications and financial printing services. All operations are carried in Hong Kong.
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.